NCT01928459 - Phase 1b Trial of BGJ398/BYL719 in Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions

Advanced Solid TumorsMetastatic Solid Tumors

Interventions

DRUG

BGJ398

BGJ398 will be administered orally once daily for the first 21 days of each 28-day cycle.

DRUG

BYL719

BYL719 will be administered orally once daily on each day of the 28-day cycle.

Trial Locations (22)

1200

Novartis Investigative Site, Brussels

3050

Novartis Investigative Site, Parkville

6500

Novartis Investigative Site, Bellinzona

10065

Memorial Sloan Kettering Cancer Center Onc Dept, New York

20141

Novartis Investigative Site, Milan

28050

Novartis Investigative Site, Madrid

33612

H. Lee Moffitt Cancer Center & Research Institute Moffitt 4, Tampa

37232

Vanderbilt University Medical Center Dept of Onc, Nashville

41013

Novartis Investigative Site, Seville

41100

Novartis Investigative Site, Modena

44805

Novartis Investigative Site, Saint-Herblain

48201

Karmanos Cancer Institute Dept of Onc, Detroit

50937

Novartis Investigative Site, Cologne

63110

Washington University School of Medicine Onc Dept, St Louis

69373

Novartis Investigative Site, Lyon

78229

Cancer Therapy & Research Center / UT Health Science Center SC, San Antonio

169610

Novartis Investigative Site, Singapore

48109-0944

University of Michigan Comprehensive Cancer Center SC, Ann Arbor

M5G 2M9

Novartis Investigative Site, Toronto

1066 CX

Novartis Investigative Site, Amsterdam

05505

Novartis Investigative Site, Seoul

08035

Novartis Investigative Site, Barcelona